Clinical Trial Update: Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pasireotide showed reduction in effluent volume from high-output enterostomies in patients not responding to standard treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• SIGNIFOR (PASIREOTIDE)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Enterostomy | Phase 2 | Status: COMPLETED